Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Selected Subjects With Advanced Solid Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03127215
What this trial is testing

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Who this might be right for
Cancers With DNA Repair-Deficiency
National Center for Tumor Diseases, Heidelberg 102
Early research (Phase 1)Study completedNCT02054806
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Who this might be right for
Solid Tumor
Merck Sharp & Dohme LLC 477
Early research (Phase 1)Study completedNCT03523390
What this trial is testing

Phase I/Ib Multiple Ascending Dose Study in China

Who this might be right for
Metastatic Solid Tumors
Merck KGaA, Darmstadt, Germany 24
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Testing effectiveness (Phase 2)UnknownNCT04092673
What this trial is testing

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Who this might be right for
Solid Tumor, Adult
Effector Therapeutics 30
Early research (Phase 1)Active Not RecruitingNCT06394414
What this trial is testing

Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd. 187
Testing effectiveness (Phase 2)Study completedNCT02419417
What this trial is testing

Study of BMS-986158 in Subjects With Select Advanced Cancers

Who this might be right for
Advanced Tumors
Bristol-Myers Squibb 83
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Early research (Phase 1)Active Not RecruitingNCT03530397
What this trial is testing

Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Who this might be right for
Selected Advanced Solid Tumors
MedImmune LLC 400
Testing effectiveness (Phase 2)Study completedNCT03797326
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Who this might be right for
Advanced Solid TumorsTriple Negative Breast CancerOvarian Cancer+5 more
Merck Sharp & Dohme LLC 611
Early research (Phase 1)Study completedNCT02583165
What this trial is testing

A Study in Adult Subjects With Select Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
MedImmune LLC 40
Early research (Phase 1)Ended earlyNCT02744287
What this trial is testing

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Who this might be right for
Metastatic Castration-resistant Prostate CancerMetastatic Prostate Cancer
Regeneron Pharmaceuticals 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT03836352
What this trial is testing

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Who this might be right for
Ovarian CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+2 more
ImmunoVaccine Technologies, Inc. (IMV Inc.) 184
Testing effectiveness (Phase 2)Ended earlyNCT02205333
What this trial is testing

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Who this might be right for
Advanced Solid TumorsAggressive B-cell Lymphomas
MedImmune LLC 48
Early research (Phase 1)Ended earlyNCT02437916
What this trial is testing

Safety Study of AMG 228 to Treat Solid Tumors

Who this might be right for
Advanced MalignancyAdvanced Solid TumorsCancer+8 more
Amgen 30
Early research (Phase 1)Study completedNCT03752398
What this trial is testing

XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Who this might be right for
Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic Carcinoma+13 more
Xencor, Inc. 198
Early research (Phase 1)Active Not RecruitingNCT05238922
What this trial is testing

Study of INCB123667 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Incyte Corporation 291
Early research (Phase 1)Study completedNCT02221960
What this trial is testing

Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
MedImmune LLC 39
Early research (Phase 1)Study completedNCT02528357
What this trial is testing

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

Who this might be right for
Neoplasms
GlaxoSmithKline 141
Early research (Phase 1)Study completedNCT03517488
What this trial is testing

XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Who this might be right for
MelanomaBreast CarcinomaHepatocellular Carcinoma+25 more
Xencor, Inc. 150
Next Page